Degeneration Clinical Trials

277 recruitingLast updated: May 21, 2026

There are 277 actively recruiting degeneration clinical trials across 51 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Dallas, Texas, United States, Boston, Massachusetts, United States, Austin, Texas, United States. Updated daily from ClinicalTrials.gov.


Degeneration Trials at a Glance

277 actively recruiting trials for degeneration are listed on ClinicalTrialsFinder across 6 cities in 51 countries. The largest study group is Not Applicable with 83 trials, with the heaviest enrollment activity in Dallas, Boston, and Austin. Lead sponsors running degeneration studies include National Eye Institute (NEI), Medical University of Vienna, and Hoffmann-La Roche.

Browse degeneration trials by phase

About Degeneration Clinical Trials

Looking for clinical trials for Degeneration? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Degeneration trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Degeneration clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 277 trials

Recruiting

Inherited Retinal Degenerative Disease Registry

Retinitis PigmentosaBatten DiseaseLeber Congenital Amaurosis+25 more
Foundation Fighting Blindness20,000 enrolled1 locationNCT02435940
Recruiting
Phase 1

Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease

Long COVIDSARS CoV-2Neurodegeneration+1 more
Stephanie B. Seminara, MD40 enrolled1 locationNCT07224490
Recruiting
Phase 1

Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

Age-Related Macular Degeneration
Benobio Co., Ltd.18 enrolled2 locationsNCT05803785
Recruiting
Phase 3

Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).

Eye DiseasesMacular Degeneration, WetSub-Macular Hemorrhage
King's College Hospital NHS Trust210 enrolled36 locationsNCT04663750
Recruiting

Cell Collection to Study Eye Diseases

Retinal DegenerationRetinitis PigmentosaRetinal Disease+1 more
National Eye Institute (NEI)930 enrolled1 locationNCT01432847
Recruiting
Phase 2

A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Geographic Atrophy secondary to Age Related Macular Degeneration
Novartis Pharmaceuticals272 enrolled16 locationsNCT07441642
Recruiting
Phase 3

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Neovascular Age-related Macular Degeneration
AbbVie561 enrolled104 locationsNCT07007065
Recruiting
Early Phase 1

The Role of Occupational Therapy for Improving Medication Management for Persons With AMD, DR and Glaucoma

Age-Related Macular Degeneration
MCPHS University50 enrolled1 locationNCT06593405
Recruiting
Phase 4

A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

Neovascular Age-related Macular Degeneration
Genentech, Inc.188 enrolled50 locationsNCT04853251
Recruiting
Phase 1Phase 2

Oral Metformin for Treatment of ABCA4 Retinopathy

Retinal DegenerationRetinal DystrophyStargardt Disease+1 more
National Eye Institute (NEI)56 enrolled2 locationsNCT04545736
Recruiting

A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)

Neovascular Age-related Macular DegenerationDiabetic Macular Edema
Hoffmann-La Roche850 enrolled59 locationsNCT06680817
Recruiting
Phase 2

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Geographic AtrophyMacular Degeneration
Janssen Research & Development, LLC274 enrolled104 locationsNCT06635148
Recruiting

Adaptive Optics Imaging of Outer Retinal Diseases

Age-Related Macular DegenerationRetinal DegenerationRetinitis Pigmentosa+7 more
Food and Drug Administration (FDA)100 enrolled2 locationsNCT05355415
Recruiting
Phase 3

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

Age related macular degeneration (AMD)Geographic Atrophy (GA)
Regeneron Pharmaceuticals975 enrolled216 locationsNCT06541704
Recruiting
Not Applicable

Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy

Geographic Atrophy secondary to Age Related Macular Degeneration
Okuvision GmbH70 enrolled5 locationsNCT07531927
Recruiting
Not Applicable

The NOTICE Study: Neurosurgery and OrThopedIcs Communication Evaluation Study Following Lumbar Fusions

Lumbar SpondylosisLumbar Spine InstabilityLumbar Spine Degeneration
Duke University224 enrolled1 locationNCT04140344
Recruiting
Not Applicable

Vision Rehabilitation Training With Multimodal Feedback in Central Vision Loss

Low visionMacular DegenerationCentral Visual Impairment
New England College of Optometry12 enrolled1 locationNCT07577219
Recruiting

Real World Data Collection on the Synergy Cervical Disc

Cervical disc degeneration
Synergy Spine Solutions200 enrolled1 locationNCT05305430
Recruiting

A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)

Geographic Atrophy secondary to Age Related Macular Degeneration
Complement Therapeutics75 enrolled9 locationsNCT07144137
Recruiting
Phase 1Phase 2

An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)

Geographic Atrophy secondary to Age Related Macular Degeneration
Complement Therapeutics75 enrolled4 locationsNCT07392255